TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: separation distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular hospitalization rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cardiovascular mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Physical activity variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective sleep indices
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Frequency of medicated nights
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma viral load <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of developing at least 1 new DRM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of new mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of developing new major IAS drug mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine volume gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction time in the incongruent condition of the Stroop test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in BMS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma zinc concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma ferritin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of superficial marginal discoloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: terminal complement complex concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum urate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 h urinary urate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of application site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of application site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of application site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Duct closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duct constriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial oxygen saturation of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological recovery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 20% improvement in American College of Rheumatology response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean decrease in Health Assessment Questionnaire‐Disability Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% reduction from baseline Psoriasis Area and Severity Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PACU resting pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid drug withdrawal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with sputum decrease > 30% from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of severe agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate in the PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: times to hospital discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Decrease in body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of agitation at week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive behavioral engagement with PARO
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: instances of agitation at week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global cognition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attention function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feelings of confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feelings of stability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feelings of reassurance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary watertight dural closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Secondary watertight dural closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adaptive dural closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Oswestry disability index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of days abstinent (PDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin K levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Heart Rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HbA(1c) changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FPG changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PPG-AUC changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in oral bioavailability of piperaquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed and enhanced absorption of dihydroartemisinin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation patterns in response to story-listening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BMD at the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: T-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Progression-Free Survival (PFS) duration
Endpoint domain: Mortality/survival
Primary endpoint: mean nadir prostate-specific antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to prostate-specific antigen relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skills attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Received a job offer
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Weeks of searching for employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: nociceptive reflex threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nociceptive reflex amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of very‐low‐density lipoprotein (VLDL) particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of low‐density lipoprotein (LDL) particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of high‐density lipoprotein (HDL) particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of >3 PAMs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of discordance between genotype interpretations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: I84V mutation association with resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stent occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PPG increment at 1 hour (ΔPG1h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glucose disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: benzodiazepine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in dietary behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worry about the baby's health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Direct medical costs of interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of metformin intervention relative to placebo
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of lifestyle intervention relative to placebo
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC0-8, AUC0-12 and Cmax for rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Epo concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of Epo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in severe depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall QOLIE‐31 score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Low seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: antisocial personality disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post‐traumatic stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose infusion rate during insulin-induced hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glucose infusion rate during hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retrograde migration of stone fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency of fragmentation and clearance of ureteral calculi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for supplemental analgesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of daily incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First uninhibited detrusor contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum bladder capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to drug withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 RNA viral load reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New AIDS events
Endpoint domain: Adverse events/effects
Primary endpoint: CD4 T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Injection site adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mild fatigue
Endpoint domain: Adverse events/effects
Primary endpoint: Contraceptive adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with contraceptive method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum iron concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Physician VAS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient VAS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TES values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival advantage over 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of recurrent ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: CGI ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% responder rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Research participation rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Odds ratio of agreeing to research
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Seroresponse rates to measles, mumps, and rubella viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroresponse rates to varicella-zoster virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Left ventricular ejection fraction after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative 6-month incidence of clinical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: better mental health functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: enhanced perceptions of social support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Spontaneous pain assessed by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand-to-floor distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle spasm determined by palpation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net protein balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in the number of voids/24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in UUI episodes/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ADAS-cog scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial technical success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: response rate of tumors treated with pegcantratinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sway when turning 180 degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to perform 180-degree turn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up and Go (single task)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASVD hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour mean heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ventricular premature beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk of atrial fibrillation/flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of laboratory-confirmed clinical influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of secondary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increase in systolic arterial pressure (AP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Terminal half-life of human FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance of human FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: FSH bioassay:immunoassay ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone volume density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reconstructed or regenerated BV/TV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tb.Th
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unemployment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: rapid sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucositis occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft versus host disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sCD36 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Deep vein thrombosis (DVT) occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Late grade 2 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical local control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three-year overall survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Sexual function mean score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary patency rates at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Secondary patency rates at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Peritonitis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Catheter survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isovolumic relaxation time (IRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial performance index (MPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: A max (late mitral peak velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease in ventromedial prefrontal response during logo-elicited anticipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: increase in behavioral disinhibition toward the logo of the consumed beverage
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: explicit hedonic devaluation of a similar nonconsumed beverage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in erectile function (IIEF-5 score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in urinary symptoms (IPSS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) impairment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Predictive ability of 4-hydroxyglutamate for pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Condom use risk ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual protection use risk ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial peak TG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduced rest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vomiting frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of thiamin deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incisor bite force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SI (Insulin Sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: vertebral BMD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: femoral BMD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Composite end point achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pad weight from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes